Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04AHQ
|
|||
Former ID |
DIB005975
|
|||
Drug Name |
LY3009120
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Lilly
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H29FN6O
|
|||
Canonical SMILES |
CC1=CC(=C(C=C1C2=C(N=C3C(=C2)C=NC(=N3)NC)C)NC(=O)NCCC(C)(C)C)F
|
|||
InChI |
1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)
|
|||
InChIKey |
HHCBMISMPSAZBF-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1454682-72-4
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Serine/threonine-protein kinase Raf (RAF) | Target Info | Modulator | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02014116) A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body. U.S. National Institutes of Health. | |||
REF 2 | Company report (eli lily) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.